Gallup puts US adult GLP-1 use for weight loss at 11% in 2026. The guide covers FDA warnings, recent recalls and the legal fight between compounders and drugmakers.
Recap by typeshit. Full story at USA TODAY.
The actor backed Ozempic in an interview while saying exercise has no shortcut. Doctors break down whether his advice holds up.
A BusinessWorld piece on FDA worries about unapproved GLP-1 weight loss drugs, including retatrutide, which is still in trials. Few details were available.
Hecht walks through studies raising concerns that Ozempic and Wegovy may be tied to a rare optic nerve problem that can affect vision.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
The FDA rated the recall Class II and reports no illnesses. The North Carolina compounder got an FDA warning letter in December 2025. Lot numbers are listed at the source.
A brief post notes growing concern over reports of serious eye problems in people taking Ozempic and similar drugs, while research into the link continues.
Loading…